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Objective 
Guanfacine has been shown to reduce hyperactive behaviors in children with attention-
deficit/hyperactivity disorder (ADHD) and possibly in children with pervasive developmental disorder 
(PDD) and hyperactivity. The aim of this exploratory study was to examine whether gene variants encoding 
the multidrug resistance protein (MDR1 or ABCB1), a drug transporter at the blood–brain barrier, are 
associated with variability in the efficacy of guanfacine in children with PDD and hyperactivity. 
Methods 
Children with PDD who participated in an 8-week open-label trial of guanfacine were genotyped 
for the C3435T single-nucleotide polymorphism (SNP) variant of the MDR1 gene, a variant reported to 
alter function of the transporter. The decrease from baseline to 8 weeks in parent-rated Aberrant Behavior 
Checklist (ABC) hyperactivity and Swanson, Nolan, and Pelham (SNAP) scores were analyzed by MDR1 
genotype. Response was compared between subjects homozygous for the minor allele T of the C34535T 
MDR1 variant (T/T) versus other genotypes (C/T and C/C). 
Results 
Disruptive behavior decreased during guanfacine treatment as assessed by several end points in 
the 25 enrolled children (23 boys and 2 girls). Genotype data were available from 22 children. Subjects 
with either C/T or C/C (n = 16) genotypes showed a three-fold greater improvement than T/T MDR1 
C3435T genotype (n = 6) (mean decrease of 15.1 ± 12.6, or 50.7% from baseline, versus 4.5 ± 5.1, or 
15.6% from baseline) in parent-rated ABC Hyperactivity scores over 8 weeks (p = 0.03). Parent-rated 
ADHD SNAP scores also differed by genotype ( p = 0.05). 
Conclusions 
Gene variants in MDR1 may influence guanfacine response on hyperactive-impulsive behaviors 
via altered membrane transport. If replicated in larger samples, additional studies would be important to 
clarify the mechanisms underlying this effect and to determine its clinical significance. 
Introduction 
An emerging body of research data suggests that guanfacine, an α2A adrenergic agonist, 
is efficacious in reducing disruptive behaviors seen in children and adolescents with attention-
deficit/hyperactivity disorder (ADHD) and other groups of children with high levels of ADHD 
symptoms (Scahill et al. 2001; Newcorn et al. 2003; Pliszka et al. 2006; Biederman et al. 2008a). 
Hyperactivity and disruptive behaviors in individuals with pervasive developmental disorders 
(PDDs) are common targets for intervention, with as many as 40% of children with PDDs shown 
to display impairing levels of such symptoms (Lecavalier et al. 2006). Pharmacotherapeutic 
approaches have been considered useful in comprehensive treatment programs for PDD, and, 
among many options, α agonists have gained popularity in community practice (Rush and 
Francis 2000). Preliminary evidence supporting such use has emerged from a recently completed 
open-label prospective trial (Scahill et al. 2006) and from prior reports (Jaselskis et al. 1992). 
This open trial conducted by the Research Units on Pediatric Psychopharmacology 
(RUPP) Autism Network showed solid reductions in parent- and teacher reported hyperactive-
impulsive behaviors in children unresponsive to previous trials of a stimulant. Symptom 
decreases from baseline were 25–36% by 8 weeks, depending on the source of ratings, and 49% 
of subjects were rated by study clinicians as clinically significantly improved on global measures 
(Scahill et al. 2006). 
Despite the apparent promise of guanfacine for the treatment of hyperactive-impulsive 
behaviors in this population, prominent variability in treatment efficacy has been noted. In the 
Scahill et al. report (2006), the improvement from baseline in Swanson, Nolan, and Pelham 
(SNAP) total ADHD symptom scores ranged from -1 to 41 points (mean 12.8). Similarly, in a 
large chart review study of children with PDD and other disorders receiving guanfacine, the rate 
of positive response ranged from 13% to 39% (average 23%), depending on the patient 
population (Posey et al. 2004). In a sample of ADHD children with co-occurring tic disorders, 
guanfacine was superior to placebo and reduced ADHD symptoms by 37% from baseline, but 
end-point ADHD ratings also showed large interindividual variability (Scahill et al. 2001). 
Another small placebo-controlled trial in children with tic disorders also showed evidence of 
interindividual variability in response (Cummings et al. 2003) 
Pharmacogenetic studies attempt to reveal sources of such interindividual variation in 
drug response, often by examining genetic variation in drug targets, drug transporters, or 
regulatory enzymes as predictors of treatment response or adverse events. The family of drug 
transporters has been the focus of many recent studies in other areas of medicine; studies of drug 
transporters in psychopharmacology are relatively sparse. P-glycoprotein, also known as multi-
drug resistance protein (MDR1) or adenosine triphosphate (ATP)- binding cassette B1 (ABCB1), 
is a transporter across the blood–brain barrier of over 70 structurally varied types of drugs 
(Schinkel and Jonker 2003; Marzolini et al. 2004). MDR1 has been well characterized in terms 
of commonly occurring genetic variants and their relationship to MDR1 expression (Hoffmeyer 
et al. 2000; Wang et al. 2007), including a common synonymous single-nucleotide 
polymorphism (SNP), C3435T, which reportedly alters substrate specificity (Kimchi-Sarfaty 
2007). The purpose of the present study was to perform an exploratory examination of the 
possible influence of MDR1 C3435T genotypes on the response of hyperactivity to guanfacine in 
the treatment of children with PDD. Outcome and safety data from this prospective open label 
trial have been published previously (Scahill et al. 2006). 
Methods 
This was a multisite, 8-week, prospective, open-label trial of guanfacine in children with 
PDD and high levels of hyperactivity and distractibility conducted by the RUPP Autism 
Network, which was funded by the National Institute of Mental Health (NIMH), and was 
approved by local site institutional review boards (IRBs) and a NIMH Data Safety Monitoring 
Board (DSMB). Eligible subjects were boys and girls between the ages of 5 and 14 years; 
Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) (American 
Psychiatric Association 1994) diagnosis of PDD (PDD–not otherwise specified [NOS], 
Asperger’s disorder or autistic disorder) based on a DSM-IV clinical diagnosis and corroborated 
by the Autism Diagnostic Interview–Revised (Lord et al. 1997), accompanied by clinically 
significant symptoms of ADHD (i.e., impulsiveness and hyperactivity) as evidenced by a score 
of at least Moderate (≥4) on the Clinical Global Impressions–Severity (CGI-S) score for ADHD 
symptoms. Subjects also had to have an average score of 1.7 or greater on the parent-rated or 
teacher-rated Hyperactive-Impulsive items of the SNAP-IV (Swanson et al. 2001; 
http://adhd.net). Subjects also were required to show an inadequate response or intolerance to 
methylphenidate (MPH). Other entry criteria required a mental age of at least 18 months by 
psychometric testing. 
Following a detailed screening that included medical, psychiatric, and developmental 
assessments, eligible subjects were seen weekly for the first 4 weeks to evaluate response and 
tolerability and then every other week until week 8. Visits included: Vital signs, height and 
weight, and a systematic review of adverse events. Outcome ratings were collected at baseline, 
and weeks 2, 4, 6, and 8 of treatment. 
Measures 
Outcome measures were the parent-rated Hyperactivity subscale of the Aberrant 
Behavior Checklist (ABC) and the Clinical Global Impressions–Improvement scale (CGI-I). The 
Hyperactivity subscale of the ABC contains 16-items that reflect hyperactivity and impulsive 
behavior (Aman et al. 1985). It was designed to measure change in treatment studies and has 
been normed in developmentally disabled populations (Marshburn et al. 1992; Brown et al. 
2002). Higher scores reflect greater symptom severity. Other important outcomes included the 
teacher-rated Hyperactivity subscale of the ABC and the parent- and teacher-rated SNAP-IV. 
The SNAP-IV is an 18-item scale based on the DSM-IV symptoms of ADHD (Swanson et al. 
2001) and has been employed in many clinical trials in typically developing childrenwithADHD 
(The MTA Cooperative Group 1999), but less commonly in children with PDD. 
Medication 
The medication regimen was determined by body weight. Children weighing below 25 kg 
started with 0.25 mg at bedtime, and increased to 0.25 mg twice a day (b.i.d.) on day 4. 
Thereafter, dosage increases were made in 0.25-mg increments, approximately every fourth day 
as tolerated, to a maximum of 3.5 mg per day, given on a three times a day (t.i.d.) schedule (e.g., 
8 am, 2 pm, and 8 pm). For children weighing ≥25 kg, the guanfacine dose schedule was similar, 
but starting with 0.5 mg at night and increases in 0.5-mg increments. The maximum dose for 
these children was 5.0 mg per day on a t.i.d. schedule. There were no planned dose increases 
after week 5. Medication decreases to manage adverse effects were permitted at any time. 
Subscale 
MDRI 
genotype 
Baseline 
(SD) 
Endpoint 
(SD) 
Change 
score 
% 
Change 
ANOVA F-test 
(controlling for 
baseline score) p value 
ABC 
Hyperactivity 
C/C or T/C* 29.8 (8.9) 14.7 (8.7) 15.1 50.7 6.63 0.03 
T/T** 28.8 (8.2) 24.3 (7.8) 4.5 15.6 
SNAP Total C/C or T/C* 37.6 (9) 19.6 (9.9) 18 47.9 4.45 0.05 
T/T** 35.3 (3.5) 27.7 (5) 7.8 22.0 
SNAP 
Inattention 
C/C or T /C* 20.5 (4.7) 11.6 (6.7) 8.9 43.4 3.18 0.09 
T/T** 19.2 (4) 15.3 (2) 3.9 20.3 
SNAP 
Hyperactivity 
C/C or T/C* 15.9 (5.2) 8.1 (4.2) 7.8 49.1 3.66 0.08 
T/T** 15.3 (4.8) 12.3 (5) 3 19.6 
*n = 16. 
**n = 6. 
Abbreviations: SD = Standard deviation; ANOVA = analysis of variance; ABC = Aberrant Behavior 
Checklist; SNAP = Swanson, Nolan, and Pelham. 
Table 1. ABC and SNAP Scores at Baseline and 8 Weeks (End Point) 
Genomic DNA was extracted from blood samples using a commercially available 
protocol (Qiagen). MDR1 was genotyped for the C3435T SNP polymorphism using the 
polymerase chain reaction (PCR) according to a published protocol (Hoffmeyer et al. 2000). A 
genotype by Intent-to-Treat design was used to analyze the data. Last observation carried 
forward (LOCF) was used to complete missing data from week 2 onward. Subjects without week 
2 outcome data were not included in the analysis. The primary analysis of the effect of genotype 
was performed using PROC GLM in SAS 9.1.3. An analysis of covariance (ANCOVA) model 
was used to predict drop in the ABC–Hyperactivity subscale or total SNAP (Inattentive plus 
Hyperactive-Impulsive items) scores from week 0 to week 8 using the MDR1 genotype as the 
independent variable while controlling for baseline ABC or SNAP scores. 
Results 
Twenty-seven subjects met eligibility criteria at baseline; the parents of 25 subjects 
provided permission to participate (mean age = 9.03 ± 3.14 years). The sample included 92% 
boys (N = 23); 72% (n = 18) were Caucasian, 24% (n = 6) were African American, and 4% (n = 
1) was Hispanic. Five subjects withdrew prior to completion due to lack of efficacy (n = 2) or 
emotional lability (n = 3). Blood draws for genotyping were successful for 22 subjects, of which 
18 completed the 8-week protocol. There were no significant differences in baseline ADHD 
ratings between those subjects who were not genotyped and those who provided DNA. 
Overall parent ratings showed declines in hyperactive-impulsive symptoms during the 8 
weeks (see Table 1). Parent-rated Hyperactivity on the ABC–Hyperactivity scale declined 58% 
from 29.5 ± 8.5 at baseline to 17.3 ± 9.4 at end point. On the parent-rated SNAP, mean scores 
declined 56% from 37.0 ± 7.8 at baseline to 21.8 ± 9.5 at end point. 
Because of prior data showing most pronounced effects of gene variants on gene 
expression for the T/T homozygotic condition (Kimchi-Sarfaty et al. 2007), we contrasted the 
change across baseline to 8 weeks using all outcome points for hyperactive-impulsive symptoms 
for two groups, the C/C and C/T versus the T/T subjects. Allele frequencies were 55% for the C 
and 45% for the T allele, respectively; the allele frequencies observed were comparable to other 
reports (Maeda and Sugiyama 2008). Genotypes were grouped as C/C or T/C (n = 16) versus 
T/T (n = 6). MDR1 genotype frequencies were in Hardy–Weinberg equilibrium; χ2 = 2.72, p = 
0.10. Genotype groups did not differ in study completion rates, age, race, gender, final dose, or 
SNAP or ABC– Hyperactivity baseline symptom ratings (see Table 2), but the T/T genotype 
showed a significantly smaller drop in the SNAP and ABC–Hyperactivity summary score versus 
the C/C and C/T subjects (mean decrease of 22.5% and 16.2% versus 47.9% and 50.0%;),; 
SNAP summary and ABC–Hyperactivity, respectively) (Fig. 1). The amount of variation in drop 
of ABC–Hyperactivity and SNAP summary scores over 8 weeks that can be attributed to the 
MDR1 genotype was 53% and 40%, respectively. Effect sizes for guanfacine on SNAP total 
scores calculated from pre- versus posttreatment differences divided by average standard 
deviations (SDs) for the C/C and C/T group was 1.73 versus 0.54 for the T/T subjects. Similarly, 
effect sizes for guanfacine on ABC parent-rated Hyperactivity were 1.48 versus 0.31 for C/C and 
C/T versus T/T groups, respectively. 
Discussion 
This prospective, open-label trial in children with PDD accompanied by hyperactivity 
and impulsive behavior showed that, despite highly significant decreases of 41% (total SNAP 
scores) and 42% (ABC–Hyperactivity) in parent ratings of ADHD symptoms during guanfacine 
administration, exploratory analyses of MDR1 gene variants showed prominent differences in 
response by genotype. The magnitude of the difference between the two genotype groups was 
greater than 1 SD in the final week-8 ratings, indicative of a large influence on treatment 
response. This is one of few observations of the influence of MDR1 on psychotropic treatment 
response. 
 C/C C/T T/T P value 
Age 8.3 ± 1.1 8.1 ± 1.2 9.0 ± 1.3 0.89 
Race 6 W, 3 B 5 W, 1 B, 1 H 4 W, 2 B 0.59 
Sex 9 M 7 M 5 M, 1 F 0.24 
Final guanfacine dose 1.58 ± 0.34 1.75 ± 0.38 1.71 ± 0.41 0.94 
Table 2. Clinical Characteristics By Genotype Groups 
Abbreviations: W = white; B = black; H = Hispanic; M = male; F = female. 
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MDR1 can also reduce absorption and increase renal excretion of some substrates, defying 
straightforward attempts to explain differences in clinical effects by genotype. 
Our report should be viewed as exploratory, given the small sample composed only of 
individuals previously shown to be unresponsive to or intolerant to MPH, with a restricted age 
range, predominance of males and Caucasian subjects, a lack of treatment blinding, and short 
observation period. Data from much larger clinical trial samples are needed to confirm or refute 
this observation and to better estimate the magnitude of the difference, if any, associated with the 
MDR1 genotype. Another limitation is the absence at present of definitive in vitro data 
confirming that guanfacine is a major substrate for MDR1 transport. If confirmed that guanfacine 
transport is influenced by MDR1, it would also be critical to examine in a controlled system the 
precise impact of MDR1 gene variants on guanfacine absorption, distribution, blood–brain levels, 
and excretion. Our ability to examine MDR1 genotype effects on adverse events is also limited in 
this pilot study. However, a large clinical trial sample could examine whether more commonly 
observed adverse events, such as sedation or mood liability, adverse events that we observed 
often mandated dose reduction or predicted intolerance, may also be associated with the MDR1 
genotype. Such observations hold obvious potential clinical importance if applicable at the level 
of the individual patient. 
Clinically, additional trials are needed to determine the benefits and safety of the α 
agonists as common treatments for pediatric neuropsychiatric disorders, especially in individuals 
with PDD with ADHD symptoms. More data are needed on the durability of benefits, as some 
reports suggest waning effects over time (Jaselskis et al. 1992), effects of sedation and fatigue on 
adherence (Biederman et al. 2008b), and to confirm the apparent acceptable cardiovascular 
safety profile from larger, recent reports (Biederman et al. 2008a; Daviss et al. 2008). As clinical 
support for guanfacine is growing, given the modest benefits of stimulants in subgroups of 
children such as PDD (Aman et al. 2003; Research Units on Pediatric Psychopharmacology 
[RUPP] Autism Network 2005), it is important to attempt to identify possible predictors of 
treatment benefit. Accumulated findings from initial guanfacine trials in children for the 
management of ADHD behaviors have varied, perhaps due to differences in clinical populations 
sampled. Although our data support MDR1 gene variants as significant moderators to guanfacine 
response, there yet may be other important variants in other genes that further contribute to 
variability in guanfacine response. Examination of other relevant target genes thought to play a 
role in guanfacine distribution, neurochemical effect, or metabolism, including α2A (ADRA2A), 
other noradrenergic system genes, CYP450 genes, and others could well reveal more robust 
genetic influences on clinical response to guanfacine. 
In conclusion, the results of this study suggest that gene variants of MDR1 may serve as a 
potent moderator of the benefits of guanfacine as a treatment for hyperactivity in children with 
PDD who do not show improvement with MPH. Besides encouraging efforts for replication, the 
results should also stimulate a greater awareness in child psychopharmacology of the potential 
importance of the family of drug transporters as key components in drug 
distribution and clinical effect. 
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